Moneycontrol PRO
HomeNewsBusinessCoronavirus India Update | Swift decline continues as 1,61,386 fresh COVID-19 cases reported in a day

Coronavirus India Update | Swift decline continues as 1,61,386 fresh COVID-19 cases reported in a day

The third COVID-19 wave in India, driven mainly by the Omicron variant, continues to decline after a rapid rise as most states seem to be on path to recovery

February 02, 2022 / 09:47 IST
(Representative image)

The swift decline of COVID-19 cases in India continues with 1,61,386 new cases recorded in the last 24 hours, which is 3.5 percent lower than the daily cases registered a day before.

The fresh infections raise the total tally of COVID-19 cases in India to 4,16,30,885 while the active cases in the country now stand at 1,6,21,603. The active cases in the country are shrinking at the rate of about 4.4 percent.

In the 24-hour period, 1,733 deaths were also recorded but that included 1,063 reconciliatory deaths from Kerala. Kerala, at 142, also reported the highest number of deaths due to COVID-19 in the 24-hour period.

The southern state also registered a rise of 10299 in the number of total active cases and was among 6 states and UTs that registered an increase in the number of active cases in a day.

A total of 4,97, 975 deaths due to the infectious disease have now been recorded in India so far.

COVID-19 Vaccine

Frequently Asked Questions

View more
How does a vaccine work?

A vaccine works by mimicking a natural infection. A vaccine not only induces immune response to protect people from any future COVID-19 infection, but also helps quickly build herd immunity to put an end to the pandemic. Herd immunity occurs when a sufficient percentage of a population becomes immune to a disease, making the spread of disease from person to person unlikely. The good news is that SARS-CoV-2 virus has been fairly stable, which increases the viability of a vaccine.

How many types of vaccines are there?

There are broadly four types of vaccine — one, a vaccine based on the whole virus (this could be either inactivated, or an attenuated [weakened] virus vaccine); two, a non-replicating viral vector vaccine that uses a benign virus as vector that carries the antigen of SARS-CoV; three, nucleic-acid vaccines that have genetic material like DNA and RNA of antigens like spike protein given to a person, helping human cells decode genetic material and produce the vaccine; and four, protein subunit vaccine wherein the recombinant proteins of SARS-COV-2 along with an adjuvant (booster) is given as a vaccine.

What does it take to develop a vaccine of this kind?

Vaccine development is a long, complex process. Unlike drugs that are given to people with a diseased, vaccines are given to healthy people and also vulnerable sections such as children, pregnant women and the elderly. So rigorous tests are compulsory. History says that the fastest time it took to develop a vaccine is five years, but it usually takes double or sometimes triple that time.

View more
Show

On a positive note though, the weekly COVID-19 test positivity rate in the country has now come down to 14.15 per cent and the daily positivity rate stood at 9.26 per cent.

The figures released by the Union health ministry showed that a total of 73.24 crore total tests have been conducted so far of which 17,42,793 tests were conducted in the last 24 hours to detect fresh infections.

Sumi Sukanya Dutta
first published: Feb 2, 2022 09:47 am

Discover the latest Business News, Sensex, and Nifty updates. Obtain Personal Finance insights, tax queries, and expert opinions on Moneycontrol or download the Moneycontrol App to stay updated!

Subscribe to Tech Newsletters

  • On Saturdays

    Find the best of Al News in one place, specially curated for you every weekend.

  • Daily-Weekdays

    Stay on top of the latest tech trends and biggest startup news.

Advisory Alert: It has come to our attention that certain individuals are representing themselves as affiliates of Moneycontrol and soliciting funds on the false promise of assured returns on their investments. We wish to reiterate that Moneycontrol does not solicit funds from investors and neither does it promise any assured returns. In case you are approached by anyone making such claims, please write to us at grievanceofficer@nw18.com or call on 02268882347